Navigation Links
MetaStat Appoints David Epstein, Ph.D. as Advisor to Lead Drug Discovery
Date:4/15/2013

MONTCLAIR, N.J., April 15, 2013 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today the appointment of David Epstein , Ph.D. as Advisor for MetaStat's Drug Discovery & Development efforts. In addition, MetaStat intends to appoint Dr. Epstein to MetaStat's board of directors as soon as practicable.

Dr. Epstein brings tremendous expertise to MetaStat at a pivotal time in the company's evolution. His R & D career spans more than 15 years and he has held leadership positions in both the pharmaceutical and biotech industries. Most recently he was Senior Vice President and Chief Scientific Officer for OSI Pharmaceuticals, now a wholly owned subsidiary of Astellas where he had strategic and operational responsibility for small molecule drug discovery and translational research encompassing OSI's portfolio of oncology R & D programs.  Prior to OSI, Dr. Epstein was a co-founder and Director of Archemix Corp, an aptamer therapeutics-focused discovery and development company.  His operational and strategic efforts at Archemix facilitated the clinical development of several therapeutic aptamers currently under evaluation for the treatment of various retinal diseases. 

"In filling this critical role, we looked for someone with experience both within and beyond the pharmaceutical/biotech industry to bring the leadership and knowledge necessary to advance our therapeutic portfolio. We found that person in David Epstein . I am confident that he will make outstanding contributions to our research and development efforts," said Dr. Oscar Bronsther , Chief Executive Officer of MetaStat.

"I am honored and excited to join MetaStat at such a defining moment in their history. I believe that my background, especially my experienc
'/>"/>

SOURCE MetaStat, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
2. OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
3. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
4. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
5. Aethlon Medical (AEMD) Note: A Medical Device Strategy to Address Metastatic Melanoma
6. MetaStat Announces Presentations at the 2012 San Antonio Breast Cancer Symposium
7. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
8. MetaStat Announces Stock Trading on OTC Bulletin Board
9. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)... , July 10, 2014 Yesterday, former ... (Moberg) medical device manufacturing facility. Rep. Kennedy and ... neurological monitors facilitate cutting-edge research in neurological disease ... and mental health advocate, Garen Staglin , ... to fostering fundamental changes that will radically accelerate ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources ... surveyed infectious disease (ID) specialists are willing to ... Orbactiv (oritavancin) for use as OPAT, approximately two-thirds ... these agents to their hospital inpatients. However, our ... OPAT patients are initiated on OPAT following hospital ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Terumo Heart, Inc. announced,today that they have ... Drug,Administration (FDA) to begin enrollment in the ... for a Bridge-to-Transplant (BTT) indication., (Logo: ... http://www.newscom.com/cgi-bin/prnh/20080303/CLM012 ), Dr. David Munjal, ...
... 29 Eisai Corporation of,North America, a wholly-owned ... the Food and Drug Administration (FDA) has accepted ... short-term (up to,eight weeks) treatment of gastroesophageal reflux ... indicated that the sNDA will receive,priority review in ...
Cached Medicine Technology:DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial 2FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents 2
(Date:7/12/2014)... 2014 Doylestown Hospital recently conducted an ... men’s health questions. Paddock tackles topics including main ... women live longer than men, and testosterone replacement therapy, ... Simple featured on Doylestown Hospital’s website, Dr. Brad ... any age. If you notice pain, bulging, or asymmetry ...
(Date:7/12/2014)... 12, 2014 Dubai is buzzing with ... is heading to the UAE. The National Basketball ... be in the UAE from 28-31 October to lead ... of diabetes awareness. The event is being organized by ... event management company based in Dubai. The announcement was ...
(Date:7/12/2014)... 12, 2014 Wright & Schulte LLC, an ... Just For Men Lawsuits (case #59776/2014), announces they have ... reports that allege the popular hair dye, Just For Men, ... their face, neck and other areas. In addition to detailing ... chemical burns , the advertisements being run by Wright & ...
(Date:7/12/2014)... Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
(Date:7/11/2014)... Recently, MagicQuinceaneraDresses.com, the popular online supplier of special occasion ... Quinceanera dresses . The company’s new items are specially ... paying a large amount of money. They are all ... The company’s online shop has become a one stop ... In addition to exquisite Quinceanera dresses, it also offers ...
Breaking Medicine News(10 mins):Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2
... Member Adds Operations and Marketing Expertise During a Key ... Growth Period for the Association, ... announced the appointment of Susan Trainer, chief executive,officer and founder, Trainer ... at a pivotal time for the Y, which,is in the middle ...
... While urinary stents and,catheters can be life-saving medical ... infections. With 100 million placed in patients each ... device-associated infections,annually. Nerites Corporation is testing its unique ... from a $100,000 small,business innovation research grant (SBIR) ...
... NASDAQ: CRME TSX: COM, VANCOUVER and DEERFIELD, IL, ... TSX: COM) and its co-development partner,Astellas Pharma US, Inc. ... U.S. Food and Drug Administration (FDA) that a decision ... (NDA) for KYNAPID(TM),(vernakalant hydrochloride). The FDA did not provide ...
... and Drug Administration as a palliative treatment for cancer ... sometimes used off-label for the treatment of peripheral vascular ... American Journal of Therapeutics finds that off-label use of ... adverse events and device malfunctions associated with the use ...
... COVER: "The Party,s Over" (p. 22). Editor-at-Large Evan ... in a precarious state. But the party,s,candidates can ... late to reinvent,the party,s core beliefs," writes Thomas. ... humble mission: to show, in effect, some humility. ...
... million Americans, most of them women, suffer from lupus, ... bodys own tissue. This week marks a significant step ... online publication of four new studies identifying genes involved ... K.Crow, M.D., associate chief of the division of Rheumatology ...
Cached Medicine News:Health News:Mount Diablo Region YMCA Names Local Business Leader, Susan Trainer, to Its Corporate Executive Board 2Health News:Mount Diablo Region YMCA Names Local Business Leader, Susan Trainer, to Its Corporate Executive Board 3Health News:Mount Diablo Region YMCA Names Local Business Leader, Susan Trainer, to Its Corporate Executive Board 4Health News:Cardiome And Astellas Announce Regulatory Update 2Health News:Cardiome And Astellas Announce Regulatory Update 3Health News:Cardiome And Astellas Announce Regulatory Update 4Health News:Study looks at off-label use of biliary stents 2Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 2Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 3Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 4Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 5Health News:NEJM editorial on significance and limitations of new lupus gene expression research 2Health News:NEJM editorial on significance and limitations of new lupus gene expression research 3Health News:NEJM editorial on significance and limitations of new lupus gene expression research 4
... BladderScan® BVI 6100 is a handheld, noninvasive ... is easy to operate, so any staff ... To view ultrasound images from exams and ... records and reimbursement, just log on to ...
... Contigen Bard Collagen Implant, the world's ... implant option for the treatment of Stress ... bulk to surrounding urethral tissue to aid ... with the body's own structure, Contigen Bard ...
... Prosthesis,The AMS DURA II ... of cobalt-chrome alloy strands ... gives patients what they ... positioning, cosmetic concealment and ...
... advanced three-part inflatable prosthesis consisting of a reservoir ... the scrotum and a pair of cylinders inserted ... look and performance of a natural erection. The ... AMS 700 Series now features the new Tactile ...
Medicine Products: